ASPIRIN ↓ Cox inhibition ↓ (PROSTACYCLIN) PGI 2 & TXA 2 (THROMBOXANE) LOW DOSE ASPIRIN.

Slides:



Advertisements
Similar presentations
Drugs for Coagulation Disorders Andrew N. Schmelz, PharmD Post-Doctoral Teaching Fellow Purdue University October 8, 2008
Advertisements

Anticoagulant, Antiplatelet, and Thrombolytic Drugs
Platelet Aggregation Inhibitors
Pathophysiology of Thrombosis Thrombosis and Thrombolysis in Acute Coronary Syndromes.
Drugs influencing coagulation Dr Sanjeewani Fonseka Department of Pharmacology.
Vascular Pharmacology
Anti-platelet drugs Dr. Ishfaq Bukhari Dec
Anticoagulants and Thrombolytic
Antiplatelet Drugs (Anti-thrombotics)
Dalia Elfawy., MD Lecturer of Anesthesia and ICU Ain Shams University 2014 RAPID REVERSAL OF ANTICOAGULATION IN TRAUMA PATIENTS.
Hemostasis and Blood Coagulation
Dr. Ishfaq Bukhari.  In healthy vasculature, circulating platelets are maintained in an inactive state by nitric oxide (NO) and prostacyclinre (PGI2)leased.
Anticoagulant, Fibrinolytic and Antiplatelet
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 53 Management of ST-Elevation Myocardial Infarction.
Drugs used in coagulation disorders By S.Bohlooli, Ph.D.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
ANTICOAGULANT, THROMBOLYTICS & ANTIPLATELET DRUGS.
Fibrinolytic Drugs (Thrombolytic Drugs ) By Prof. Hanan Hagar Dr.Abdul latif Mahesar 1.
Antiplatelet Drugs - Principles Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Drugs for Coagulation disorders. There are a number of different categories of drugs which modify the coagulation process: I. Anticoagulants II. Antiplatelet.
Coagulation Mechanisms
Disseminated Intravascular Coagulation. XIIa Coagulation cascade IIa Intrinsic system (surface contact ) XII XI XIa Tissue factor IX IXa VIIa VII VIIIVIIIa.
Dr. Mahmoud H. Taleb1 Pharmacology II Lecture 1 Pharmacology of Blood Dr. Mahmoud H. Taleb Assistant Professor of Pharmacology and Toxicology Head of Department.
Platelet Aggregation Inhibitors
ANTIPLATELET DRUGS.
Presented by: Passant Mounir Nagy Under the supervision of: Prof. Dr/ Seham Hafez.
Developed by: Dawn Johnson, RN, MSN, Ed.  Internally and externally  Prevent bleeding from wounds which could lead to shock or even death.
Drugs Used to Treat Thromboembolic Disorders Chapter 27 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar.
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.
ANTIPLATELETES AGENTS
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.
Blood Vessel Injury IX IXa XI XIa X Xa XII XIIa Tissue Injury Tissue Factor Thromboplastin VIIa VII X Prothrombin Thrombin Fibrinogen Fribrin monomer.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Fibrinolytic Drugs (Thrombolytic Drugs ) By Prof. Hanan Hagar.
THROMBOLYTIC DRUGS Pathophysiologic Rationale
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar
Anticoagulants, Thrombolytic Agents and Antiplatelet Drugs
Dr. Laila M. Matalqah Ph.D. Pharmacology
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to To describe the role of platelets in.
Prof. Abdulrahman Almotrefi
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar Dr
Drugs Used in Coagulation Disorders Presented by Dr. Sasan Zaeri PharmD, PhD.
Rationale for the Clinical Evaluation of Combination GP IIb-IIIa Inhibitor and Low-Dose Fibrinolytic Therapy in ST-Elevation Myocardial Infarction.
Platelets. Fig Hemostasis the process by which the bleeding is stopped from broken vessels. steps involved: Vascular spasm. Platelets plug formation.
Drugs Used in Coagulation Disorders
Anticoagulant, Antiplatelet, and Thrombolytic Drugs.
II. Antiplatelet Drugs.
Anticoagulants, Antiplatelets, and Thrombolytics
ACUTE MYOCARDIAL INFARCTION
Management of ST-Elevation Myocardial Infarction
Antithrombotic drugs Fibrinolytics
THROMBOLYTIC DRUGS (Fibrinolytic drugs) By Prof. Hanan Hagar Dr
Thrombolytic therapy Summary. (Slides 2,3 and 4) MCQs. (slide 5)
Med Chem Tutoring for Anticoagulants, Antiplatelets, and Thrombolytics
Drugs Used in Coagulation Disorders
Hemodynamic disorders (1 of 3)
and anti-thrombotic pharmocology Tom Williams
Anticoagulant Reversal
Prof. Abdulrahman Almotrefi
Anti-Platelet Drugs Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Antiplatelet Drugs Dr. : Asmaa Fady MD., MSC, M.B, B.Ch
Hemostasis Hemostasis depends on the integrity of Blood vessels
Section B: Science update
FIBRINOLYTIC DRUGS VIJAYA LECHIMI RAJ.
Presentation transcript:

ASPIRIN ↓ Cox inhibition ↓ (PROSTACYCLIN) PGI 2 & TXA 2 (THROMBOXANE) LOW DOSE ASPIRIN

1)PREVENT ARTERIAL THROMBOSIS IHD, STROKE 2) UNSTABLE ANGINA 3) RECENT MI 4) TIA 5) ARIFICIAL VALVES

6) PTCA 7) PERIPHERAL ARTERIAL OCCLUSIVE DISEASE 8) CHRONIC LIMB ISCHEMIA

Aspirin ADR

DIPYRIDAMOLE - VASODILATOR - THALLIUM IMAGING - INHIBIT PLATELET ADHESION TO VESSEL WALL ↑ cAMP ↓ PLATELET CALCIUM INHIBIT AGGREGATION + ASPIRIN – STROKE, TIA ? SUPERIOR

CLOPIDOGREL & TICLOPIDINE INHIBIT ADP – INDUCED EXPRESSION OF PLATELET GP RECEPTORS ↓ DECREASE FIBRINOGEN BINDING ↓ DECREASE PLATELET AGGREGATION

CLOPIDOGREL → PRODRUG, TICLOPIDINE → NEUTROPENIA ↓ CBC – 2 WEEKS UPTO 3 MONTHS

THROMBOTIC STROKE SICKLE CELL ANEMIA ACS INTERMITTENT CLAUDICATION PCI CHRONIC ARTERIAL OCCLUSION OPEN HEART SURGERY AV SHUNT

ABCIXIMAB - PCI + Aspirin & Heparin - in MI - Bleeding, thrombocytopenia, hypotension, Brady cardia

TIROFIBAN & EPTIFIBATIDE - Competitive, reversible inhibitors of fibrinogen binding to GPII b / III a - ACS – unstable angina, NSTEMI - Angioplasty & stenting - Bleeding

FIBRINOLYTICS: Streptokinase Alteplase Urokinase Reteplase Anistreplase Tenecteplase

Streptokinase 1.5 million units over 60 min Alteplase 15mg bolus 0.75mg/1kg – 30 min 0.5mg/kg- 60 min

Reteplase – 10mg bolus 10mg after 30min Tenecteplase – IV bolus 0.5 mg /kg

Coagulation factor concentrates Desmopressin

HEMOSTATIC AGENTS: ε - Aminocaproic acid Aprotinin TOPICAL ABSORBABLE: Thrombin Microfibrillar collagen hemostat Absorbable gelatin Oxidized cellulose

THROMBOLYTIC THERAPY ADV- Availability, rapid administration DISADV – Intracranial hemorrhage - Uncertainty of whether normal coronary flow has been restored - Reocclusion

-Most effective within 12 hour (relative mortality decreased by 18%) - Little benefit beyond 12 hour Not for resolved chest pain, ST segment depression

Fibrin selective agents should be used with anticoagulants – UFH, LMWH, fondraparinux & bivalirudin Monitoring of thrombolytic therapy!

Patency is 30% PCI patency 95% (TIMI 3)

Persistent angina Persistent ischemic changes on ECG <50% Reduction in ST elevation min after initiation of thrombolysis ---rescue PCI.

Routine coronary angiography & PCI within 24h of thrombolysis

Complications: Intracranial bleeding 0.7 – 0.9% Major bleeding requiring treatment 10% Venipuncture & arterial puncture.

Diagnosis of coagulation defects Prolonged APTTDefective Intrinsic Pathway No change in PT No change in APTTDefective Extrinsic Pathway Prolonged PT Prolonged APTTDefective in Common pathway Prolonged PT

Absolute C/I: 1) H/o intracranial hemorrhagic / hemorrhagic stroke 2) Ischemic stroke within 3mo 3) AVMs, aneurysms, tumor 4) Closed head injury within 3 mo 5) Aortic dissection 6) severe uncontrolled HT – SBP > 180, DBP > 110 7) Active bleeding / bleeding diathesis 8) Acute pericarditis.

Blood Vessel Injury IX IXa XI XIa X Xa XII XIIa Tissue Injury Tissue Factor Thromboplastin VIIa VII X Prothrombin Thrombin Fibrinogen Fribrin monomer Fibrin polymer XIII Intrinsic PathwayExtrinsic Pathway Factors affected By Heparin Vit. K dependent Factors Affected by Oral Anticoagulants

Thrombosis  Arterial Thrombosis : Adherence of platelets to arterial walls - White in color - Often associated with MI, stroke and ischemia  Venous Thrombosis : Develops in areas of stagnated blood flow (deep vein thrombosis), Red in color- Associated with Congestive Heart Failure, Cancer, Surgery.